Literature DB >> 19957060

Per2 inhibits k562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction.

Cheng-ming Sun1, Shi-feng Huang, Jian-ming Zeng, Din-bing Liu, Qing Xiao, Wen-jun Tian, Xi-dan Zhu, Zong-gan Huang, Wen-li Feng.   

Abstract

Per2 regulates other molecular and biochemical processes beyond their established role in the regulation of the mammalian circadian clock, herein we investigated the growth inhibiting potential of Per2 in human K562 leukemia cells and the underlying mechanisms. The results showed that over-expression of Per2 induced not only cell cycle arrest at G2/M phase but also an increase in apoptosis, which was confirmed by characteristic morphological changes, FCM and evident DNA fragmentation. Further experiments confirmed both up-regulation of P53 and down-regulation of CylinB1and C-myc. On the other hand, while P53 was found to be down-regulated. CylinB1 and C-myc were up-regulated. after Per2 knockdown. In leukemia mice, Per2 transfection was shown to suppress cellular proliferation and accelerate apoptosis of K562 cells. Moreover, fewer leukemia cells were found to have infiltrated into the livers and spleens of the mice from the Per2 transfected group as compared with those from the control group. In summary, Per2 displayed a significant anti-tumor effect through cell cycle arrest and apoptosis induction in K562 cells. These data further support the emerging role of the circadian clock in critical aspects of cancer development and thorough research is underway on the mechanism of Per2 in the leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19957060     DOI: 10.1007/s12253-009-9227-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  30 in total

Review 1.  Waiting for anaphase: Mad2 and the spindle assembly checkpoint.

Authors:  J V Shah; D W Cleveland
Journal:  Cell       Date:  2000-12-22       Impact factor: 41.582

Review 2.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 3.  Coordination of circadian timing in mammals.

Authors:  Steven M Reppert; David R Weaver
Journal:  Nature       Date:  2002-08-29       Impact factor: 49.962

Review 4.  Cell cycle checkpoints: preventing an identity crisis.

Authors:  S J Elledge
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

5.  CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.

Authors:  Donna E Hansel; Surajit Dhara; RuChih C Huang; Raheela Ashfaq; Mari Deasel; Yutaka Shimada; Harold S Bernstein; John Harmon; Malcolm Brock; Arlene Forastiere; M Kay Washington; Anirban Maitra; Elizabeth Montgomery
Journal:  Am J Surg Pathol       Date:  2005-03       Impact factor: 6.394

6.  Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock.

Authors:  B Zheng; U Albrecht; K Kaasik; M Sage; W Lu; S Vaishnav; Q Li; Z S Sun; G Eichele; A Bradley; C C Lee
Journal:  Cell       Date:  2001-06-01       Impact factor: 41.582

Review 7.  The circadian clock: pacemaker and tumour suppressor.

Authors:  Loning Fu; Cheng Chi Lee
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

8.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.

Authors:  Chi-Hwa Wu; Jan van Riggelen; Alper Yetil; Alice C Fan; Pavan Bachireddy; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-30       Impact factor: 11.205

Review 9.  Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics.

Authors:  F Lévi; E Filipski; I Iurisci; X M Li; P Innominato
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2007

Review 10.  Mammalian circadian biology: elucidating genome-wide levels of temporal organization.

Authors:  Phillip L Lowrey; Joseph S Takahashi
Journal:  Annu Rev Genomics Hum Genet       Date:  2004       Impact factor: 8.929

View more
  29 in total

1.  Construction of a plasmid for overexpression of human circadian gene period2 and its biological activity in osteosarcoma cells.

Authors:  An-yuan Cheng; Yan Zhang; Hong-jun Mei; Shuo Fang; Peng Ji; Jian Yang; Ling Yu; Wei-chun Guo
Journal:  Tumour Biol       Date:  2015-01-07

Review 2.  Clock genes: their role in colorectal cancer.

Authors:  Theodoros Karantanos; George Theodoropoulos; Dimitrios Pektasides; Maria Gazouli
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

3.  Cell cycle-related metabolism and mitochondrial dynamics in a replication-competent pancreatic beta-cell line.

Authors:  Chiara Montemurro; Suryakiran Vadrevu; Tatyana Gurlo; Alexandra E Butler; Kenny E Vongbunyong; Anton Petcherski; Orian S Shirihai; Leslie S Satin; Daniel Braas; Peter C Butler; Slavica Tudzarova
Journal:  Cell Cycle       Date:  2017-09-29       Impact factor: 4.534

Review 4.  Circadian gene variants in cancer.

Authors:  Nicole M Kettner; Chinenye A Katchy; Loning Fu
Journal:  Ann Med       Date:  2014-06-05       Impact factor: 4.709

5.  Model-driven experimental approach reveals the complex regulatory distribution of p53 by the circadian factor Period 2.

Authors:  Tetsuya Gotoh; Jae Kyoung Kim; Jingjing Liu; Marian Vila-Caballer; Philip E Stauffer; John J Tyson; Carla V Finkielstein
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-09       Impact factor: 11.205

Review 6.  Understanding the significance of biological clock and its impact on cancer incidence.

Authors:  Shalie Malik; James Stokes Iii; Upender Manne; Rajesh Singh; Manoj K Mishra
Journal:  Cancer Lett       Date:  2021-12-11       Impact factor: 8.679

Review 7.  PER2: a potential molecular marker for hematological malignancies.

Authors:  Huihui Jiang; Xin Yang; Miaomiao Mi; Xiaonan Wei; Hongyuan Wu; Yu Xin; Chengming Sun
Journal:  Mol Biol Rep       Date:  2021-10-12       Impact factor: 2.316

Review 8.  The circadian clock in cancer development and therapy.

Authors:  Loning Fu; Nicole M Kettner
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 9.  Exploring the link between chronobiology and drug delivery: effects on cancer therapy.

Authors:  Tânia Albuquerque; Ana R Neves; Telma Quintela; Diana Costa
Journal:  J Mol Med (Berl)       Date:  2021-07-02       Impact factor: 4.599

10.  CRY2 missense mutations suppress P53 and enhance cell growth.

Authors:  Alanna B Chan; Gian Carlo G Parico; Jennifer L Fribourgh; Lara H Ibrahim; Michael J Bollong; Carrie L Partch; Katja A Lamia
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.